BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: de Leuw P, Stephan C. Protease inhibitors for the treatment of hepatitis C virus infection. GMS Infect Dis 2017;5:Doc08. [PMID: 30671330 DOI: 10.3205/id000034] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
Number Citing Articles
1 Chhetri A, Chettri S, Rai P, Mishra DK, Sinha B, Brahman D. Synthesis, characterization and computational study on potential inhibitory action of novel azo imidazole derivatives against COVID-19 main protease (Mpro: 6LU7). J Mol Struct 2021;1225:129230. [PMID: 32963413 DOI: 10.1016/j.molstruc.2020.129230] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
2 Mengist HM, Dilnessa T, Jin T. Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease. Front Chem 2021;9:622898. [PMID: 33889562 DOI: 10.3389/fchem.2021.622898] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
3 Narayanan A, Narwal M, Majowicz SA, Varricchio C, Toner SA, Ballatore C, Brancale A, Murakami KS, Jose J. Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay. Commun Biol 2022;5:169. [PMID: 35217718 DOI: 10.1038/s42003-022-03090-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
4 Dražić T, Kopf S, Corridan J, Leuthold MM, Bertoša B, Klein CD. Peptide-β-lactam Inhibitors of Dengue and West Nile Virus NS2B-NS3 Protease Display Two Distinct Binding Modes. J Med Chem 2020;63:140-56. [DOI: 10.1021/acs.jmedchem.9b00759] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
5 Abuo-rahma GEA, Mohamed MFA, Ibrahim TS, Shoman ME, Samir E, Abd El-baky RM. Potential repurposed SARS-CoV-2 (COVID-19) infection drugs. RSC Adv 2020;10:26895-916. [DOI: 10.1039/d0ra05821a] [Cited by in Crossref: 18] [Article Influence: 9.0] [Reference Citation Analysis]
6 Vuorinen E, Valtonen S, Hassan N, Mahran R, Habib H, Malakoutikhah M, Kopra K, Härmä H. Protease Substrate-Independent Universal Assay for Monitoring Digestion of Native Unmodified Proteins. Int J Mol Sci 2021;22:6362. [PMID: 34198602 DOI: 10.3390/ijms22126362] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Narayanan A, Toner SA, Jose J. Structure-based inhibitor design and repurposing clinical drugs to target SARS-CoV-2 proteases. Biochem Soc Trans 2022:BST20211180. [PMID: 35015073 DOI: 10.1042/BST20211180] [Reference Citation Analysis]
8 Bhowmik D, Sharma RD, Prakash A, Kumar D. "Identification of Nafamostat and VR23 as COVID-19 drug candidates by targeting 3CLpro and PLpro.". J Mol Struct 2021;1233:130094. [PMID: 33612858 DOI: 10.1016/j.molstruc.2021.130094] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
9 Kumar A, Sharma M, Richardson CD, Kelvin DJ. Potential of Natural Alkaloids From Jadwar (Delphinium denudatum) as Inhibitors Against Main Protease of COVID-19: A Molecular Modeling Approach. Front Mol Biosci 2022;9:898874. [DOI: 10.3389/fmolb.2022.898874] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Hucke FIL, Bugert JJ. Current and Promising Antivirals Against Chikungunya Virus. Front Public Health 2020;8:618624. [PMID: 33384981 DOI: 10.3389/fpubh.2020.618624] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]